Geraldine A. Goss

246 Clayton Road
Clayton, VIC 3168, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study.

Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study.

Journal: Translational oncology

Published: August 13, 2025

Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study.

Perioperative ctDNA as a prognostic biomarker in endometrial cancer - the CODEC study.

Journal: Translational oncology

Published: August 13, 2025

Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.

Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 16, 2025

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).

Journal: Cancers

Published: November 16, 2022

Whisker Sensing by Force and Moment Measurements at the Whisker Base.

Whisker Sensing by Force and Moment Measurements at the Whisker Base.

Journal: Soft robotics

Published: August 22, 2022

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.

Journal: Journal for immunotherapy of cancer

Published: March 31, 2021

Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.

Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.

Journal: International journal of radiation oncology, biology, physics

Published: August 27, 2020

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: June 03, 2020

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.

Journal: British journal of cancer

Published: April 05, 2016

Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.

Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.

Journal: Gynecologic oncology

Published: December 14, 2012

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 09, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026